Bill Maughan
Stock Analyst at Canaccord Genuity
(n/a)
# 4,379
Out of 4,820 analysts
14
Total ratings
12.5%
Success rate
-44.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $4.07 | +539.61% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.11 | +610.90% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $1.28 | +603.13% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $30.13 | +122.37% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $27.22 | +289.42% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $0.50 | +4,697.12% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $8.36 | +617.70% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $43.54 | +3.35% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $4.07
Upside: +539.61%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.11
Upside: +610.90%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.28
Upside: +603.13%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $30.13
Upside: +122.37%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $27.22
Upside: +289.42%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $0.50
Upside: +4,697.12%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $8.36
Upside: +617.70%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $43.54
Upside: +3.35%